PCI对冠心病患者血清MMP-9、hs-CRP、HMGB1水平的影响及其预后分析
目的探讨经皮冠状动脉介入术(PCI)对冠心病(CHD)患者血清基质金属蛋白酶-9(MMP-9)、高敏C反应蛋白(hs-CRP)、高迁移率族蛋白1(HMGB1)水平的影响及其预后分析。方法抽取2014年5月-2016年4月蛇口人民医院127例CHD患者,根据病史、临床症状、心电图检查、冠脉造影等分为SAP(稳定型心绞痛,n=43)、UAP(不稳定型心绞痛,n=43)、AMI(急性心肌梗死,n=41)三组,均行PCI治疗,分别于手术前5min及术后48h抽取静脉血检测血清MMP-9、hs-CRP ...
陈丽芳, 宋晓华, 黄于朗
doaj
目的探讨经皮冠状动脉介入治疗(PCI)后的急性ST段抬高型心肌梗死(STEMI)患者入院血钾水平与长期死亡的关系。方法连续入选2015年1月1日至2015年12月31日在吉林大学第一医院行PCI的STEMI患者1125例,根据患者入院后首次测定血钾水平(mmol/L)分为5组:
许慧娟 +4 more
doaj
[β‑blockers after percutaneous coronary intervention does not reduce risks of all-cause mortality or major adverse cardiovascular events in patients with stable coronary artery disease]. [PDF]
Gao X +7 more
europepmc +1 more source
[Application advances of fractional flow reserve in endovascular treatment of lower-extremity arterial disease]. [PDF]
Zhang L +6 more
europepmc +1 more source
冠脉支架术后口服多种P2Y12受体拮抗剂发生抵抗的 影响因素分析
摘 要:【目的】 探讨急性冠脉综合征(ACS)行经皮冠状动脉介入治疗术(PCI)后患者口服多种P2Y12受体拮抗剂发生抵抗的影响因素? 【方法】 入选174例ACS行PCI术患者,男女比例为3.5∶1;平均年龄(67.8 ± 11.8)岁(40 ~ 91岁)?氯吡格雷治疗占113例(64.9%),普拉格雷治疗占20例(11.5%),替格瑞洛治疗占41例(23.6%)?于PCI术后连续服用阿司匹林和一种P2Y12受体拮抗剂至少5 d或以上(中位数为11 d,范围5~180 d ...
doaj
[Evaluation of coronary microvascular dysfunction for assessing prognosis of ST-segment elevation acute myocardial infarction following reperfusion therapy: insights from QFR-AMR]. [PDF]
Gao S +8 more
europepmc +1 more source
[Practical guideline on the prevention and management of diabetic foot in China (Ⅰ)]. [PDF]
Chinese Burn Association +2 more
europepmc +1 more source
[Clinical efficacy of multidisciplinary team collaboration in the treatment of deep sternal wound infection]. [PDF]
Tong L +6 more
europepmc +1 more source
[Clinical efficacy and safety of transcatheter aortic valve replacement for patients with severe pure native aortic regurgitation]. [PDF]
Chen J +6 more
europepmc +1 more source
[Analysis of clinical characteristics of 12 cases of first bite syndrome]. [PDF]
Huang C, He J, Qi X, Hu P, Ding K.
europepmc +1 more source

